Menu
Meet the Program Commitee for 2021!
项目委员会
-
Matt Baldwin, MS • Biomedical Data Stewardship Senior Manager

Amgen, United States -
Amy Bertha • Executive Director, Regulatory Policy and Science

Bayer, United States -
Poonam Bordoloi, PharmD • Executive Director, Head of Global Medical Affairs Capabilities

Organon & Co., United States -
David Bowers, PharmD • Senior Director, Operations

PPD, United States -
Kristina Bowyer • Vice President, Patient Advocacy & Engagement

Ionis Pharmaceuticals, Inc., United States -
Philip (P.J.) Brooks, PhD • Deputy Director, Division of Rare Diseases Research Innovation

National Center for Advancing Translational Sciences (NCATS), NIH, United States -
Bill Byrom, PhD • Vice President, Product Intelligence and Positioning; Principal, eCOA Science

Signant Health , United Kingdom -
Meghana Chalasani, MHA • Associate Director for Clinical Trial Innovation, Office of New Drugs, CDER

FDA, United States -
Andrew Chang, PhD • Vice President, Quality and Regulatory Compliance

Novo Nordisk, United States -
Karla Childers, MS • Vice President, Bioethics, Policy & Partnerships

Johnson & Johnson, United States -
Leah Christl, PhD • Exec Director, Global Biosimilars Regulatory Affairs & Regulatory & R&D Policy

Amgen, United States -
Freda Cooner, PhD • Statistician

FDA, United States -
Stephanie Y. Crawford, PhD, MPH, MS • Professor, Pharmacy Systems, Outcomes and Policy

University of Illinois at Chicago, United States -
Julie Dietrich, MS • Senior Director, Clinical Development

United States -
Sonya Eremenco, MA • Executive Director, PRO Consortium

Critical Path Institute, United States -
Jennifer Farmer, MS • Chief Executive Officer

Friedreich's Ataxia Research Alliance (FARA), United States -
Ron Fitzmartin, PhD, MBA • Principal Consultant

Decision Analytics, United States -
David Fryrear, MS • Chief Quality Officer

Astellas, United States -
M. Scott Furness, PhD • Deputy Director, Office of New Drug Products, OPQ, CDER

FDA, United States -
Alicia Gilsenan, PhD, MS, RPh, FISPE • Vice President, Epidemiology

RTI Health Solutions, United States -
Renmeet Grewal, PharmD, MS • Division Director, Office of Regulatory Operations (DRO-II), OND, CDER

FDA, United States -
Sabine Haubenreisser, PhD, MSc • Principal Scientific Administrator, Stakeholders and Communication Division

European Medicines Agency, Netherlands -
Alan Hochberg • Principal Scientific Enablement Director, Scientific Enablement and Processes

Genentech, A Member of the Roche Group, United States -
Michelle Hoiseth • General Manager, Project-Based Services

Cytel, United States -
Kenneth Hu, PharmD, MBA • Senior Manager (US Reg Lead), Global Regulatory Strategy & Policy, Oncology

Bristol Myers Squibb, United States -
Jeremy Jokinen, PhD, MS • Vice President and Head Global Patient Safety

Argenx, United States -
Darryl L'Heureux, PhD, MPharm, MSc • Director, Clinical Science, Medical Writing, and Publications

Ambrx, Inc, United States -
Erik Laughner • Project Manager, Business Operations Staff, OD, CBER

FDA, United States -
Cathryn C Lee, MSN •

United States -
Rebecca Lipsitz, PhD • Sr. Director, Regulatory Policy & Intelligence

AstraZeneca, United States -
Sheila Mahoney Jewels, MBA • Drug Development Multi-Functionalist

LifeSciHub , United States -
Ingrid Markovic, PhD • Independent Expert

United States -
Christopher Marrone, PharmD, RPh • Outcomes Liaison Advisor – National Accounts, Value, Evidence and Outcomes (VEO)

Eli Lilly and Company, United States -
Chris Matheus, MBA • Chief Commercial and Networking Officer

United States -
K. Kimberly McCleary • Founder and Chief Executive Officer

The Kith Collective, LLC, United States -
Lindsay McNair, MD, MPH, MS • Principal Consultant

Equipoise Consulting, United States -
Ann Meeker-O'Connell, MS • Executive Director, Monitoring Excellence Head

Novartis, United States -
Christine Moore, PhD • Executive Director, Global External Advocacy and Standards

Organon & Co., United States -
Jean M. Mulinde, MD • Associate Director, Division of Clinical Compliance Evaluation, OSI

FDA, United States -
Erin Mulrooney, MSc, PMP • Director, Portfolio Management

Daiichi Sankyo, Inc, United States -
Nobumasa Nakashima • Professor

Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan -
Anita Nelsen • Executive Vice President, Translational Medicine

Parexel, United States -
David O Olaleye, PhD, MSc • Senior Manager and Principal Research Statistician

SAS Institute Inc., United States -
Sissi Pham, PharmD • Chief Executive Officer

AESARA, United States -
Paul Phillips • Director, Office of Program Operations, OND, CDER

FDA, United States -
Margaret Richards, PhD, MPH • Open to Work

Pharmacoepidemiology / RWE, United States -
Steven L. Roberds, PhD • Chief Scientific Officer

Tuberous Sclerosis Alliance, United States -
Earl Seltzer, MBA • Senior Director, Partnerships and Innovation

CTI, United States -
Nancy Slater, MBA, PMP • Senior Director, Portfolio Program Management Therapeutic Area Head

AbbVie, Inc., United States -
Nancy Pire Smerkanich, DrSc, MS • Assistant Professor Regulatory & Quality Sciences

University of Southern California School of Pharmacy, United States -
Evelyn Soo, PhD, MS • Director, Bureau of Gastroenterology, Infection and Viral Diseases, HPFB

Health Canada, Canada -
Mat Soukup, PhD • Deputy Director, Division of Biometrics VII, OB, OTS CDER

FDA, United States -
Jeffrey N. Stuart, PhD • Associate Vice President, Global Regulatory Affairs

Merck Sharp & Dohme LLC , United States -
Ling Su, PhD • Research Fellow

Yeehong Business School, China -
Rachel Turow, JD, MPH • Of Counsel, FDA Regulatory

Skadden, United States -
Daniel Urban, PhD • Pharmacology/Toxicology Reviewer, OTAT, CBER

FDA, United States -
Paula Walker, MA • Global Head of Risk Based Quality Management

Roche Products Ltd., United Kingdom -
Nancy Watanabe, MS, PMP • Independent Consultant

Independent Consultant, United States -
Keith Wenzel • Volunteer

DIA Study Endpoints Community, United States -
Meredith Yearsley Smith, PhD, MPA, FISPE • Fellow and faculty member

USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, United States -
Judith Zander, MD • Director, Office of Pharmacovigilance and Epidemiology, OSE, CDER

FDA , United States
